We are live on
!
Find out more
CC
Casdin Capital Portfolio holdings
AUM
$2B
1-Year Est. Return
147.21%
This Fund
S&P 500
This Quarter
Est. Return
+55.67%
1 Year Est. Return
+147.21%
3 Year Est. Return
+369.71%
5 Year Est. Return
+164.99%
10 Year Est. Return
+6,568.53%
AUM
$2B
AUM Growth
+$677M
(+51%)
Cap. Flow
+$55.8M
Cap. Flow
% of AUM
2.79%
Top 10 Holdings %
Top 10 Hldgs %
77.36%
Holding
46
New
6
Increased
9
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GeneDx Holdings
WGS
|
+$39.8M |
| 2 |
Relay Therapeutics
RLAY
|
+$23.5M |
| 3 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$17.8M |
| 4 |
SION
Sionna Therapeutics
SION
|
+$16M |
| 5 |
Scholar Rock
SRRK
|
+$15.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
10x Genomics
TXG
|
+$32.1M |
| 2 |
BioLife Solutions
BLFS
|
+$30.4M |
| 3 |
Qiagen
QGEN
|
+$14.4M |
| 4 |
Guardant Health
GH
|
+$14.1M |
| 5 |
TEM
Tempus AI
TEM
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Prime Medicine
PRME
$570M
| $11.7M | 0.59% |
3,167,175
| – | – |
|
27
Absci
ABSI
$1.59B
| $11.3M | 0.56% |
973,260
| – | – |
|
28
Quest Diagnostics
DGX
$27.3B
| $10.6M | 0.53% |
50,000
| – | – |
|
29
Sarepta Therapeutics
SRPT
$2.18B
| $8.45M | 0.42% |
+470,000
| New | +$8.89M |
|
30
uniQure
QURE
$3.06B
| $6.91M | 0.35% |
+150,000
| New | +$3.93M |
|
31
Intellia Therapeutics
NTLA
$1.72B
| $6.01M | 0.3% |
355,000
| – | – |
|
32
Moderna
MRNA
$63.1B
| $5.25M | 0.26% |
75,000
| – | – |
|
33
Disc Medicine
IRON
$2.66B
| $4.75M | 0.24% |
65,000
| – | – |
|
34
Monte Rosa Therapeutics
GLUE
$1.07B
| $4.5M | 0.23% |
186,014
| – | – |
|
35
Century Therapeutics
IPSC
$340M
| $3.01M | 0.15% |
1,228,190
| – | – |
|
|
CTNM
36
Contineum Therapeutics
CTNM
$497M
| $2.43M | 0.12% |
148,333
| – | – |
|
|
BBOT
37
BridgeBio Oncology
BBOT
$392M
| $2.15M | 0.11% |
282,312
| – | – |
|
38
Editas Medicine
EDIT
$418M
| $1.44M | 0.07% |
+445,000
| New | +$1.3M |
|
39
Pacific Biosciences
PACB
$429M
| $1.22M | 0.06% |
723,767
| – | – |
|
|
KARD
40
Kardigan Inc
KARD
$1.56B
| $1.19M | 0.06% |
+50,000
| New | +$1.16M |
|
41
Recursion Pharmaceuticals
RXRX
$1.9B
| $607K | 0.03% |
165,323
| – | – |
|
42
Ginkgo Bioworks
DNA
$528M
| $362K | 0.02% |
36,493
| – | – |
|
43
Tenaya Therapeutics
TNYA
$151M
| $268K | 0.01% |
361,969
| – | – |
|
44
MoonLake Immunotherapeutics
MLTX
$1.05B
| – | – |
-450,000
| Closed | -$8.39M |
|
|
45
Qiagen
QGEN
$9.16B
| – | – |
-360,000
| Closed | -$14.4M |
|
|
TEM
46
Tempus AI
TEM
$14.6B
| – | – |
-294,127
| Closed | -$13.3M |
|
Similar funds
KOCAA
NL
CAM
SB
BGGS
CC
JWA
FOF
Casdin Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Casdin Capital held 46 positions worth $2B, up 51% from $1.32B the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Casdin Capital's Q2 2026 filing shows 6 new, 9 increased, 3 reduced and 3 closed positions. Its largest new stake was Parabilis Medicines Inc: 645,690 shares worth $17.7M. The largest sale was 10x Genomics, an estimated $32.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Casdin Capital's largest Q2 2026 buy was Parabilis Medicines Inc: 645,690 shares worth $17.7M.
- Casdin Capital added most to GeneDx Holdings in Q2 2026, an estimated $39.8M increase.
- Casdin Capital's biggest Q2 2026 reduction was 10x Genomics, cutting an estimated $32.1M.
- Casdin Capital fully exited Qiagen in Q2 2026, selling an estimated $14.4M.
- Casdin Capital's ten largest holdings make up 77% of its $2B portfolio in Q2 2026.
- Casdin Capital opened 6 new positions and closed 3 in Q2 2026.
- Casdin Capital's portfolio value rose 51% quarter-over-quarter to $2B.
Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.